- recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
This study is looking at two medicines, pembrolizumab and brentuximab vedotin, for people with Hodgkin lymphoma that has come back or hasn't responded to other treatments. It wants to see which medicine works better at stopping the cancer from growing and helping people live longer.
Sweden · Czechia · Poland - recruitingPHASE1, PHASE2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study looks at a new drug, AZD3470, alone or with other cancer medicines, for people with blood cancers like lymphoma. It aims to see if it's safe, how it works, and if it helps shrink the cancer. This is an early-stage trial.
United States · Australia · Brazil - active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
United States · Canada - recruitingPHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study looks at new treatments for Hodgkin lymphoma that has returned or not responded to previous treatment. It compares two newer drugs, pembrolizumab and brentuximab vedotin, with the standard treatment to see if they work better.
Australia · Canada - not yet recruitingPHASE2
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
This study is looking at a new way to treat advanced Hodgkin Lymphoma using a drug called pembrolizumab alongside standard chemotherapy. It aims to see how well this new treatment works and if it can stop the cancer from returning.
Germany - active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
United States · Brazil · Colombia - recruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
United Kingdom - authorisedTherapeutic confirmatory (Phase III)
Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
This study is looking at new ways to treat advanced Hodgkin lymphoma. It compares two different treatment plans to see which one works best at getting rid of the cancer and has fewer side effects. We want to find out if a new combination of medicines is better for patients.
Poland - recruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
United States · Australia · Belgium